MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
申请人:Combs Andrew Paul
公开号:US20090286778A1
公开(公告)日:2009-11-19
The present invention relates to macrocyclic compounds of Formula I:
or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
申请人:Lemieux Rene M.
公开号:US20150031627A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS MÉTHODES D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2015010297A1
公开(公告)日:2015-01-29
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
Copper nanoparticles (CuNPs) catalyzed chemoselective reduction of nitroarenes in aqueous medium
作者:Randhir Rai、Dillip Kumar Chand
DOI:10.1007/s12039-021-01940-3
日期:2021.9
established, under appropriate reaction conditions, using rice (Oryza sativa) as an economic source of reducing as well as a stabilizing agent. Optical and microscopic techniques are employed for the characterization of the synthesized CuNPs and the sizes of the particles were found to be in the range of 8 ± 2 nm. The nanoparticles are used as a catalyst for chemoselective reduction of aromaticnitro compounds
[EN] THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE<br/>[FR] COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION
申请人:AGIOS PHARMACEUTICALS INC
公开号:WO2013107291A1
公开(公告)日:2013-07-25
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.